The clinical study for the effect of oral supplementary drugs containing lutein on macular pigment density

The clinical study for the effect of oral supplementary drugs containing lutein on macular pigment density - The effect of oral supplementary drug containing lutein on macular pigment density

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011512

Enrollment

Registered

2013-08-29

Start date

2013-05-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with early age-related macular degeneration and healthy volunteer participants

Interventions

daily dose with supplementary tablets which contains lutein 20mg, for 6 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with early age-related macular degeneration: one or more indistinct soft drusen at macular area, or distinct soft drusen(s) with pigment epithelial abnormality. healthy volunteer participants: healthy adults in age between 20 and 61 year old.

Exclusion criteria

Exclusion criteria: patients with early age-related macular degeneration: patients with cataract which could prevent clear fundus autofluorescent image. patients with some kinds of systemic disease which could cause macular abnormality. healthy volunteer participants: who is affected with some kinds of dieases which could cause macular abnormalities, pregnant, possibly pregnant.

Design outcomes

Primary

Measure	Time frame
macular pigment optical density, serum consentration of lutein and some other amino acids, contrast sensitivity, best corrected visua acuities.	—

Countries

Japan

Contacts

Public ContactShigeto Fujimura

the university of tokyo hospital The department of ophthalmology

shigeto-tky@umin.ac.jp0338155411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026